Zoledronic acid 5mg
ApprovedWithdrawn 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Prosthetic Fixation After Cementless Total Hip Arthroplasty
Conditions
Prosthetic Fixation After Cementless Total Hip Arthroplasty
Trial Timeline
Jul 30, 2015 → Jan 28, 2020
NCT ID
NCT02333344About Zoledronic acid 5mg
Zoledronic acid 5mg is a approved stage product being developed by Novartis for Prosthetic Fixation After Cementless Total Hip Arthroplasty. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02333344. Target conditions include Prosthetic Fixation After Cementless Total Hip Arthroplasty.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02333344 | Approved | Withdrawn |
Competing Products
1 competing product in Prosthetic Fixation After Cementless Total Hip Arthroplasty
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VANCOMYCIN + CEFTRIAXONE + CLINDAMYCIN + SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE) + FLUOROQUINOLONE + LINEZOLID + RIFAMPIN | Pfizer | Phase 2 | 51 |